When puberty comes too early
For most children, puberty is a normal — if sometimes overwhelming — part of growing up, typically beginning around ages 8 to 13 in girls. But for some girls, it starts much earlier.
Central precocious puberty (CPP) is a condition where the brain begins sending puberty hormones too soon — sometimes as early as age 6 or 7. When puberty starts this early, it can cause rapid bone aging, which paradoxically leads to a shorter final adult height. Bones reach their growth limit early, before the child has grown to her full potential.
Why treatment matters beyond just timing
Beyond height, early puberty can affect a child's emotional and social development. A girl dealing with physical changes years before her peers often experiences anxiety and social difficulty — challenges that can persist well into adolescence.
The goal of treatment is to put the brakes on the hormonal signal driving early puberty, allowing the body to grow more normally and reach a healthier adult height.
The drug that does the braking
Triptorelin is a type of medication called a GnRH agonist (gonadotropin-releasing hormone agonist). It works by overwhelming the hormonal signal that triggers puberty — flooding the receptor so continuously that the system essentially shuts off.
Imagine a car alarm that never stops. Eventually, the neighbors ignore it. Triptorelin works similarly: by providing a constant, unrelenting hormonal signal, it paradoxically silences the response.
Monthly injections of triptorelin have been the standard approach for years. But monthly clinic visits are a real burden for families — especially those in rural areas or with demanding work schedules.
A quarterly formulation — one shot every 90 days — has been developed, but until recently there was limited evidence directly comparing it to the monthly version in terms of how well it actually works.
Who was studied and how
This retrospective study from Fuzhou First General Hospital in China enrolled 70 girls diagnosed with central precocious puberty between March 2023 and 2025. Thirty-two received the quarterly formulation (15 mg every 90 days), and 38 received the monthly formulation (3.75 mg every 28 days). Outcomes — including hormone levels, bone age, predicted adult height, and uterine and ovarian size — were assessed at baseline, 6 months, and 12 months.
After 12 months, both groups showed comparable suppression of the two key puberty hormones — luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH levels reached virtually identical levels in both groups (0.30 IU/L in each), suggesting the quarterly dose suppressed the hormonal signal just as effectively as monthly dosing.
Both groups also showed similar effects on bone maturation rates and predicted adult height — meaning the quarterly formulation did not allow bones to age faster or reduce height predictions compared to the monthly version.
This does not mean the quarterly formulation is approved or available everywhere — treatment decisions should always be made with a specialist.
Why this is worth paying attention to
For a family managing a child's precocious puberty, the difference between a monthly clinic visit and a quarterly one is enormous. Fewer disruptions to school schedules. Fewer needles. Fewer co-pays. If a quarterly injection truly works just as well as a monthly one, that's a meaningful quality-of-life improvement — not just a convenience.
What this means for families
If your daughter is being treated for central precocious puberty, ask her pediatric endocrinologist whether the quarterly formulation is an option in your country and whether it might be appropriate for her specific situation. Dosing decisions should always be made based on individual hormone response and monitoring results.
Do not adjust treatment schedules without consulting your child's specialist.
The limits of this study
Seventy patients across two groups is a small sample. Because this was a retrospective study — reviewing existing patient records rather than running a controlled prospective trial — it cannot fully account for all differences between patients. The study was conducted at a single center in China, and the results may not apply equally to girls in other populations or healthcare settings.
The abstract was also partially truncated in the version available for this review, meaning some reported outcome data may not be fully captured here.
What comes next
Larger, multicenter prospective trials comparing quarterly and monthly triptorelin would be the logical next step. If those studies confirm equivalent efficacy and safety across more diverse populations, regulatory bodies in more countries may extend approval to the quarterly formulation — giving pediatric endocrinologists a more flexible treatment toolkit and giving families a meaningful reduction in the burden of care.